Nautilus Biotechnology is emerging as Seattle’s newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biomedical research and transform drug development. The Seattle company, which will trade on Nasdaq under the ticker NAUT starting Thursday, has some familiar faces at the helm who’ve successfully guided public companies before. Co-founded in 2016 by Institute for Systems Biology alum Parag Mallick and Isilon Systems co-founder Sujal Patel, Nautilus is developing a new way to analyze the proteome, the set of proteins in a biological sample.